Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Basilea Pharmaceutica AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Basilea Pharmaceutica AG - Product Pipeline Review - 2014', provides an overview of the Basilea Pharmaceutica AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Basilea Pharmaceutica AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Basilea Pharmaceutica AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Basilea Pharmaceutica AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Basilea Pharmaceutica AG's pipeline products Reasons to buy - Evaluate Basilea Pharmaceutica AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Basilea Pharmaceutica AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Basilea Pharmaceutica AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Basilea Pharmaceutica AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Basilea Pharmaceutica AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Basilea Pharmaceutica AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Basilea Pharmaceutica AG Snapshot 5 Basilea Pharmaceutica AG Overview 5 Key Information 5 Key Facts 5 Basilea Pharmaceutica AG - Research and Development Overview 6 Key Therapeutic Areas 6 Basilea Pharmaceutica AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Basilea Pharmaceutica AG - Pipeline Products Glance 13 Basilea Pharmaceutica AG - Late Stage Pipeline Products 13 Pre-Registration Products/Combination Treatment Modalities 13 Filing rejected/Withdrawn Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Basilea Pharmaceutica AG - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Basilea Pharmaceutica AG - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Basilea Pharmaceutica AG - Drug Profiles 20 isavuconazonium sulfate 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ceftobiprole medocaril 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 BAL-101553 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 BAL-30072 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule For Inflammatory Diseases 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules for Hematological and Solid Cancers 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Inhibit Beta-Lactamase for Bacterial Infections 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Basilea Pharmaceutica AG - Pipeline Analysis 30 Basilea Pharmaceutica AG - Pipeline Products by Target 30 Basilea Pharmaceutica AG - Pipeline Products by Route of Administration 31 Basilea Pharmaceutica AG - Pipeline Products by Molecule Type 32 Basilea Pharmaceutica AG - Pipeline Products by Mechanism of Action 33 Basilea Pharmaceutica AG - Recent Pipeline Updates 34 Basilea Pharmaceutica AG - Dormant Projects 43 Basilea Pharmaceutica AG - Discontinued Pipeline Products 44 Discontinued Pipeline Product Profiles 44 BAL-2299 44 Basilea Pharmaceutica AG - Locations And Subsidiaries 45 Head Office 45 Other Locations & Subsidiaries 45 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 48 Disclaimer 48
List of Tables Basilea Pharmaceutica AG, Key Information 5 Basilea Pharmaceutica AG, Key Facts 5 Basilea Pharmaceutica AG - Pipeline by Indication, 2014 8 Basilea Pharmaceutica AG - Pipeline by Stage of Development, 2014 9 Basilea Pharmaceutica AG - Monotherapy Products in Pipeline, 2014 10 Basilea Pharmaceutica AG - Out-Licensed Products in Pipeline, 2014 11 Basilea Pharmaceutica AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Basilea Pharmaceutica AG - Pre-Registration, 2014 13 Basilea Pharmaceutica AG - Filing rejected/Withdrawn, 2014 14 Basilea Pharmaceutica AG - Phase III, 2014 15 Basilea Pharmaceutica AG - Phase II, 2014 16 Basilea Pharmaceutica AG - Phase I, 2014 17 Basilea Pharmaceutica AG - Preclinical, 2014 18 Basilea Pharmaceutica AG - Discovery, 2014 19 Basilea Pharmaceutica AG - Pipeline by Target, 2014 30 Basilea Pharmaceutica AG - Pipeline by Route of Administration, 2014 31 Basilea Pharmaceutica AG - Pipeline by Molecule Type, 2014 32 Basilea Pharmaceutica AG - Pipeline Products by Mechanism of Action, 2014 33 Basilea Pharmaceutica AG - Recent Pipeline Updates, 2014 34 Basilea Pharmaceutica AG - Dormant Developmental Projects,2014 43 Basilea Pharmaceutica AG - Discontinued Pipeline Products, 2014 44 Basilea Pharmaceutica AG, Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
